Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Open Biol ; 4(7)2014 Jul.
Article in English | MEDLINE | ID: mdl-25056286

ABSTRACT

GLUT2 is a facilitative glucose transporter, expressed in polarized epithelial cells of the liver, intestine, kidney and pancreas, where it plays a critical role in glucose homeostasis. Together with SGLT1/2, it mediates glucose absorption in metabolic epithelial tissues, where it can be translocated apically upon high glucose exposure. To track the subcellular localization and dynamics of GLUT2, we created an mCherry-hGLUT2 fusion protein and expressed it in multicellular kidney cysts, a major site of glucose reabsorption. Live imaging of GLUT2 enabled us to avoid the artefactual localization of GLUT2 in fixed cells and to confirm the apical GLUT2 model. Live cell imaging showed a rapid 15 ± 3 min PKC-dependent basal-to-apical translocation of GLUT2 in response to glucose stimulation and a fourfold slower basolateral translocation under starvation. These results mark the physiological importance of responding quickly to rising glucose levels. Importantly, we show that phloretin, an apple polyphenol, inhibits GLUT2 translocation in both directions, suggesting that it exerts its effect by PKC inhibition. Subcellular localization studies demonstrated that GLUT2 is endocytosed through a caveolae-dependent mechanism, and that it is at least partly recovered in Rab11A-positive recycling endosome. Our work illuminates GLUT2 dynamics, providing a platform for drug development for diabetes and hyperglycaemia.


Subject(s)
Epithelial Cells/cytology , Glucose Transporter Type 2/analysis , Glucose Transporter Type 2/metabolism , Glucose/metabolism , Kidney/cytology , Optical Imaging/methods , Animals , Cell Line , Dogs , Endocytosis , Epithelial Cells/metabolism , Glucose Transporter Type 2/genetics , Humans , Kidney/metabolism , Luminescent Proteins/analysis , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Microscopy, Fluorescence/methods , Protein Transport , Recombinant Fusion Proteins/analysis , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Red Fluorescent Protein
2.
Methods Mol Biol ; 945: 287-302, 2013.
Article in English | MEDLINE | ID: mdl-23097113

ABSTRACT

The liver is the largest internal organ in mammals, serving a wide spectrum of vital functions. Loss of liver function due to drug toxicity or viral infection is a major cause of death in the United States. The development of Bioartificial Liver (BAL) devices and the demand for pharmaceutical and cosmetic toxicity screening require the development of long-term hepatocyte culture techniques. However, primary hepatocytes rapidly lose their cuboidal morphology and liver-specific functions over a few days in culture. Accumulation of stress fibers, loss of metabolic function, and cell death are known phenomena. In recent years, several techniques were developed that can support high levels of liver-specific gene expression, metabolic and synthetic function for several weeks in culture. These include the collagen double-gel configuration, hepatocyte spheroids, coculture with endothelial cells, and micropatterned cocultures with 3T3-J2 fibroblasts. This chapter covers the current status of hepatocyte culture techniques, including: hepatocyte isolation, media formulation, oxygen supply, heterotypic cell-cell interactions, and basic functional assays.


Subject(s)
Cell Culture Techniques/methods , Coculture Techniques/methods , Hepatocytes/cytology , Albumins/metabolism , Animals , Cell Separation , Enzyme-Linked Immunosorbent Assay , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Oxygen/pharmacology , Perfusion , Rats , Time Factors , Urea/metabolism
3.
PLoS One ; 6(4): e18033, 2011 Apr 06.
Article in English | MEDLINE | ID: mdl-21494673

ABSTRACT

The abundant flavonoid aglycone, naringenin, which is responsible for the bitter taste in grapefruits, has been shown to possess hypolipidemic and anti-inflammatory effects both in vitro and in vivo. Recently, our group demonstrated that naringenin inhibits hepatitis C virus (HCV) production, while others demonstrated its potential in the treatment of hyperlipidemia and diabetes. However, naringenin suffers from low oral bioavailability critically limiting its clinical potential. In this study, we demonstrate that the solubility of naringenin is enhanced by complexation with ß-cyclodextrin, an FDA approved excipient. Hydroxypropoyl-ß-cyclodextrin (HPßCD), specifically, increased the solubility of naringenin by over 400-fold, and its transport across a Caco-2 model of the gut epithelium by 11-fold. Complexation of naringenin with HPßCD increased its plasma concentrations when fed to rats, with AUC values increasing by 7.4-fold and C(max) increasing 14.6-fold. Moreover, when the complex was administered just prior to a meal it decreased VLDL levels by 42% and increased the rate of glucose clearance by 64% compared to naringenin alone. These effects correlated with increased expression of the PPAR co-activator, PGC1α in both liver and skeletal muscle. Histology and blood chemistry analysis indicated this route of administration was not associated with damage to the intestine, kidney, or liver. These results suggest that the complexation of naringenin with HPßCD is a viable option for the oral delivery of naringenin as a therapeutic entity with applications in the treatment of dyslipidemia, diabetes, and HCV infection.


Subject(s)
Flavanones/pharmacokinetics , beta-Cyclodextrins/metabolism , 2-Hydroxypropyl-beta-cyclodextrin , Administration, Oral , Animals , Biological Availability , Biological Transport/drug effects , Body Weight/drug effects , Caco-2 Cells , Diet , Glucose/administration & dosage , Glucose/pharmacology , Humans , Lipoproteins, VLDL/metabolism , Male , Rats , Rats, Sprague-Dawley , Solubility/drug effects , Solutions , beta-Cyclodextrins/administration & dosage , beta-Cyclodextrins/pharmacology
4.
Semin Intervent Radiol ; 27(3): 268-75, 2010 Sep.
Article in English | MEDLINE | ID: mdl-22550366

ABSTRACT

About 75% of lung cancer patients are not surgical candidates, either due to advanced disease or medical comorbidities. Furthermore, conventional treatments that can be offered to these patients are beneficial only to a small percentage of them. Thermal ablation is a minimally invasive treatment that is commonly used in this group of patients, and which has shown promising results. Currently, the most widely used ablation techniques in the treatment of lung malignancies are radiofrequency ablation (RFA), microwave ablation, and cryoablation. Although the most studied technique is RFA, recent studies with microwave ablation and cryoablation have shown some advantages over RFA. This article reviews the application of thermal ablation in the thorax, including patient selection, basic aspects of procedure technique, imaging follow-up, treatment outcomes, and comparison of ablation techniques.

SELECTION OF CITATIONS
SEARCH DETAIL
...